+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Alpha-1 Antitrypsin Drugs Market 2018-2022 - Product Image

Global Alpha-1 Antitrypsin Drugs Market 2018-2022

  • ID: 4613294
  • Report
  • August 2018
  • Region: Global
  • 107 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • and Kamada
  • CSL
  • GRIFOLS
  • Shire
  • MORE
About Alpha-1 Antitrypsin Drugs

Alpha-1 antitrypsin augmentation therapy is used for treating emphysema caused due to deficiency of alpha-1 antitrypsin proteins in the bloodstream.

The analysts forecast the Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 10.64% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the alpha-1 antitrypsin drugs market. To calculate the market size, the report considers the revenue generated from the sales of alpha-1 antitrypsin drugs across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, alpha-1 antitrypsin drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Shire
  • CSL
  • GRIFOLS
  • Kamada
Market drivers
  • Improving diagnosis of alpha-1 antitrypsin deficiency
  • For a full, detailed list, view the full report
Market challenges
  • High cost of drugs
  • For a full, detailed list, view the full report
Market trends
  • Strategic alliances and mergers
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • and Kamada
  • CSL
  • GRIFOLS
  • Shire
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION ROUTE OF ADMINISTRATION
  • Segmentation by route of administration
  • Comparison by Route of Administration
  • Parenteral – Market size and forecast 2017-2022
  • Inhalation
  • Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CSL
  • GRIFOLS
  • Kamada
  • Shire
PART 15: PIPELINE ANALYSIS
  • Pipeline analysis
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global alpha-1 antitrypsin drugs market – Market characteristics
Exhibit 02: Global alpha-1 antitrypsin drugs market – Market segments
Exhibit 03: Global alpha-1 antitrypsin drugs market – Market definition - Inclusions and exclusions checklist
Exhibit 04: Global alpha-1 antitrypsin drugs market – Market size 2017
Exhibit 05: Validation techniques employed for market sizing 2017
Exhibit 06: Global alpha-1 antitrypsin drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 07: Global alpha-1 antitrypsin drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 08: Five forces analysis 2017
Exhibit 09: Five forces analysis 2022
Exhibit 10: Global alpha-1 antitrypsin drugs market – Bargaining power of buyers
Exhibit 11: Global alpha-1 antitrypsin drugs market – Bargaining power of suppliers
Exhibit 12: Global alpha-1 antitrypsin drugs market – Threat of new entrants
Exhibit 13: Global alpha-1 antitrypsin drugs market – Threat of substitutes
Exhibit 14: Global alpha-1 antitrypsin drugs market – Threat of rivalry
Exhibit 15: Market condition – Five forces 2017
Exhibit 16: Route of Administration – Market share 2017-2022 (%)
Exhibit 17: Comparison by Route of Administration
Exhibit 18: Parenteral RoA - Market size and forecast 2017-2022 ($ mn)
Exhibit 19: Parenteral RoA – Year over year growth 2018-2022 (%)
Exhibit 20: Market opportunity by RoA
Exhibit 21: Global alpha-1 antitrypsin drugs market - Customer landscape
Exhibit 22: Global alpha-1 antitrypsin drugs market – Market share by geography 2017-2022 (%)
Exhibit 23: Global alpha-1 antitrypsin drugs market – Regional comparison
Exhibit 24: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 26: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 28: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 30: Global alpha-1 antitrypsin drugs market – Market opportunity
Exhibit 31: Vendor landscape
Exhibit 32: Landscape disruption
Exhibit 33: Vendors covered
Exhibit 34: Vendor classification
Exhibit 35: Market positioning of vendors
Exhibit 36: CSL overview
Exhibit 37: CSL – Business segments
Exhibit 38: CSL – Organizational developments
Exhibit 39: CSL – Geographic focus
Exhibit 40: CSL – Segment focus
Exhibit 41: CSL – Key offerings
Exhibit 42: GRIFOLS overview
Exhibit 43: GRIFOLS – Business segments
Exhibit 44: GRIFOLS – Organizational developments
Exhibit 45: GRIFOLS – Geographic focus
Exhibit 46: GRIFOLS – Segment focus
Exhibit 47: GRIFOLS – Key offerings
Exhibit 48: Kamada overview
Exhibit 49: Kamada – Business segments
Exhibit 50: Kamada – Organizational developments
Exhibit 51: Kamada – Segment focus
Exhibit 52: Kamada – Key offerings
Exhibit 53: Shire – overview
Exhibit 54: Shire – Business segments
Exhibit 55: Shire – Organizational developments
Exhibit 56: Shire – Geographic focus
Exhibit 57: Shire – Segment focus
Exhibit 58: Shire – Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • and Kamada
  • CSL
  • GRIFOLS
  • Shire
  • MORE
New Report Released: - Global Alpha-1 Antitrypsin Drugs Market 2018-2022

The author of the report recognizes the following companies as the key players in the global alpha-1 antitrypsin drugs market: Shire, CSL, GRIFOLS, and Kamada.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is strategic alliances and mergers. Companies are now working together in the form of collaboration or licensing for development of new drugs across location.”

According to the report, one driver influencing this market is the improving diagnosis of alpha-1 antitrypsin deficiency. Detection is an important step in treating any disease or deficiency and several awareness programs have been conducted across the globe to recognize and differentiate alpha-1 antitrypsin deficiency from other diseases.

Further, the report states that one challenge affecting this market is the high cost of drugs. The high cost of alpha-1 antitrypsin therapies is responsible for impeding the market growth. The manufacture of plasma proteins is expensive and account almost four times the cost of manufacturing the pharmaceutical drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Shire
  • CSL
  • GRIFOLS
  • and Kamada
Note: Product cover images may vary from those shown
Adroll
adroll